Wechselwirkungen · Ifirmasta (previously Irbesartan Krka)
Ifirmasta 75 mg film-coated tablets Ifirmasta 150 mg film-coated tablets Ifirmasta 300 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 6
HOS-209822 · Präparat HOS-154383
Additional information on irbesartan interactions: In clinical studies, the pharmacokinetic of irbesartan is not affected by hydrochlorothiazide. Irbesartan is mainly metabolised by CYP2C9 and to a lesser extent by glucuronidation. No significant pharmacokinetic or pharmacodynamic interactions were observed when irbesartan was coadministered with warfarin, a medicinal product metabolised by CYP2C9. The effects of CYP2C9 inducers such as rifampicin on the pharmacokinetic of irbesartan have not been evaluated. The pharmacokinetic of digoxin was not altered by coadministration of irbesartan.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): irbesartan (HOS-086921) hydrochlorothiazide (HOS-086937) digoxin (HOS-086172) warfarin (HOS-085950)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-05-06T17:53:00Z · SHA-256 e433703ffd9bd808c0192a313a2ee367aa7dd908ac40549e8c4904a5f65b0d76 · Passage dc8143e03e0f990f7b8aaecbec02b84b25bf3ee7a876e8f0bd173c147c07472f · Zeichen 3194–3789 im Abschnitt